Loading…
Stop Tampering of Prescription Pills Act of 2013
Legislative Progress
Introduced
February 4, 2013
Latest Action
February 8, 2013
Primary Sponsor
William R. KeatingDemocratic(MA)
Momentum (last 30 days)
0
score
0 actions · 0 new cosponsors · 0 votes
Speed vs cohort
42pct
4d open
vs 5,821 other HR bills in the 113th — cohort avg 49d
No CRS summary is available for this bill yet. The source title, actions, sponsors, and text versions below come from Congress.gov.
These links require the bill number to appear in the filing's source-reported specific issue text. Client expenses and lobbying-firm income are separate disclosure fields.
Filing registrants (15)
Bills with similar content found using semantic analysis.
Sources: Congress.gov
2015 · second_quarter · Health Issues
The Prescription Drug Marketing Act;conterfit/pedigree issues Drug importation issues; Drug safety and inspection of drug manufacturing facilities; Prescription Drug Abuse;H.R. 1285 - To amend the Controlled Substances Act; H.R. 486 Stop Tampering of Prescription Pills Act of 2013;H.R. 672 - Prescription Drug Abuse Prevention and Treatment Act of 2013S. 216 - Safe Prescribing Act of 2013;S. 504 - Fair And Immediate Release of Generic Drugs Act;S. 348
Client expense: $2,500,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2015 · first_quarter · Health Issues
The Prescription Drug Marketing Act;conterfit/pedigree issues Drug importation issues; Drug safety and inspection of drug manufacturing facilities; Prescription Drug Abuse;H.R. 1285 - To amend the Controlled Substances Act; H.R. 486 Stop Tampering of Prescription Pills Act of 2013;H.R. 672 - Prescription Drug Abuse Prevention and Treatment Act of 2013S. 216 - Safe Prescribing Act of 2013;S. 504 - Fair And Immediate Release of Generic Drugs Act;S. 348
Client expense: $580,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2014 · fourth_quarter · Health Issues
Issues relating to bioequivalence and related administrative procedures. Issues relating to prescription drug abuse. Issues relating to incentives for tamper-resistant formulations. H.R. 486: Stop Tampering of Prescription Pills Act of 2013.Issues relating to Medicare Part D rebates. Issues relating to health information technology. H.R. 1919: Safeguarding Americas Pharmaceuticals Act of 2013. Compounding and drug supply chain legislation. H.R. 3204: Drug Quality and Security Act. Issues relating to products containing high doses of acetaminophen. Issues relating to the labeling of generic drugs. Issues relating to eliminating Medicare coverage for vacuum erection systems.
Client expense: Not reported · Firm income: $30,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2014 · fourth_quarter · Health Issues
Pharmaceutical Distribution Supply Chain Security (H.R. 1919 / S. 957 / S. 959); Electronic distribution of prescribing information; School Access to Emergency Epinephrine (H.R. 2094); Biosimilars; H.R. 8; H.R. 486 - the Stop Tampering of Prescription Pills (STOPP) Act; S.504 - Fair and Immediate Release of Generic Drugs Act; S.621 - The Safe Prescribing Act of 2013 /H.R.1285 H.R.460 - Patients Access to Treatments Act of 2013; House Energy & Commerce Committee's 21st Century Cures initiative
Client expense: Not reported · Firm income: $60,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2014 · fourth_quarter · Pharmacy
Prescription Drug Abuse, STOPP Act HR486; S.Con.Res.8 (FY 2014 Budget) (provisions relating to healthcare and pharmeceuticals); Drug labeling, electronic labeling proposals; counterfeit drugs; HR 1919, Safeguarding America's Pharmaceuticals Act, and S.959, Pharmaceutical Quality, Security and Accountability Act; H. 3717 Helping Families in Mental Health Crisis Act of 2013; HR4800, FY15 Appropriations for Agriculture, Rural Development, Food & Drug Administration and Related Agencies;HR 2985, Combinaation Drug Development Incentive Act of 2013; and "21st Century Cures."
Client expense: $890,000 · Firm income: Not reported
| Republican |
| KY |
| Jack Kingston | Republican | GA |
| James P. McGovern | Democratic | MA |
| Janice D. Schakowsky | Democratic | IL |
| John F. Tierney | Democratic | MA |
| Joseph P. Kennedy III | Democratic | MA |
| Michael G. Grimm | Republican | NY |
| Nick J. Rahall II | Democratic | WV |
| Robert B. Aderholt | Republican | AL |
| Stephen F. Lynch | Democratic | MA |
| Thomas J. Rooney | Republican | FL |
| Vern Buchanan | Republican | FL |
Government targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE, U.S. Trade Representative (USTR), White House Office
2014 · fourth_quarter · Health Issues
The Prescription Drug Marketing Act;conterfit/pedigree issues Drug importation issues; Drug safety and inspection of drug manufacturing facilities; Prescription Drug Abuse;H.R. 1285 - To amend the Controlled Substances Act; H.R. 486 Stop Tampering of Prescription Pills Act of 2013;H.R. 672 - Prescription Drug Abuse Prevention and Treatment Act of 2013S. 216 - Safe Prescribing Act of 2013;S. 504 - Fair And Immediate Release of Generic Drugs Act;S. 348
Client expense: $520,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2014 · fourth_quarter · Health Issues
general health issues, including, but not limited to, coverage and reimbursement; drug importation; research and development; biosimilars; Stop Tampering of Prescription Pills Act of 2013 (H.R. 486) Safeguarding America's Pharmaceuticals Act of 2013; Able Act H.R. 647; Medicaid Generic Drug Price Fairness Act H.R.5748, S.2984
Client expense: Not reported · Firm income: $40,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2014 · fourth_quarter · Health Issues
Issues relating to bioequivalence and related administrative procedures; issues relating to prescription drug abuse; issues relating to incentives for tamper-resistant formulations; H.R. 486 (Stop Tampering of Prescription Pills Act of 2013); issues relating to Medicare Part D rebates; issues relating to health information technology; H.R. 1919 (Safeguarding America's Pharmaceuticals Act of 2013); compounding and drug supply chain legislation; H.R. 3204 (Drug Quality and Security Act); issues relating to products containing high doses of acetaminophen; issues relating to the labeling of generic drugs; issues relating to eliminating Medicare coverage for vacuum erection systems; FDA Proposed Generic Drug Labeling Rule.
Client expense: $540,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2014 · fourth_quarter · Pharmacy
Controlled Drug Substances Act (21 USC 13) Stop Tampering of Prescription Pills Act of 2013 (H.R.486)
Client expense: Not reported · Firm income: $50,000
Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2014 · fourth_quarter · Health Issues
Interstate Medical Licensure Compact, state based medical licensure and regulation, telemedicine and telehealth, prescription drug abuse, prescriber and patient education, responsible opioid prescription, improvements to provider screening to prevent Medicare/Medicaid fraud, graduate medical education, health license portability, HR2011, S1089, HR3077, HR486
Client expense: $165,000 · Firm income: Not reported
Government targets: Agency for Healthcare Research & Quality (AHRQ), Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Drug Enforcement Administration (DEA), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Office of Natl Drug Control Policy (NDCP), SENATE, Substance Abuse & Mental Health Services Administration (SAMHSA), Veterans Affairs, Dept of (VA), White House Office
2014 · fourth_quarter · Health Issues
Issues relating to bioequivalence and related administrative procedures. Issues relating to prescription drug abuse. Issues relating to incentives for tamper-resistant formulations. H.R. 486 - Stop Tampering of Prescription Pills Act of 2013. Issues relating to Medicare Part D rebates. Issues relating to health information technology. H.R. 1919 - Safeguarding Americas Pharmaceuticals Act of 2013.
Client expense: Not reported · Firm income: $30,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2014 · third_quarter · Health Issues
The Prescription Drug Marketing Act;conterfit/pedigree issues Drug importation issues; Drug safety and inspection of drug manufacturing facilities; Prescription Drug Abuse;H.R. 1285 - To amend the Controlled Substances Act; H.R. 486 Stop Tampering of Prescription Pills Act of 2013;H.R. 672 - Prescription Drug Abuse Prevention and Treatment Act of 2013S. 216 - Safe Prescribing Act of 2013;S. 504 - Fair And Immediate Release of Generic Drugs Act;S. 348
Client expense: $390,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2014 · third_quarter · Pharmacy
Prescription Drug Abuse, STOPP Act HR486; S.Con.Res.8 (FY 2014 Budget) (provisions relating to healthcare and pharmeceuticals); Drug labeling, electronic labeling proposals; counterfeit drugs; HR 1919, Safeguarding America's Pharmaceuticals Act, and S.959, Pharmaceutical Quality, Security and Accountability Act; H. 3717 Helping Families in Mental Health Crisis Act of 2013; HR4800, FY15 Appropriations for Agriculture, Rural Development, Food & Drug Administration and Related Agencies;HR 2985, Combinaation Drug Development Incentive Act of 2013; and "21st Century Cures."
Client expense: $880,000 · Firm income: Not reported
Government targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE, U.S. Trade Representative (USTR), White House Office
2014 · third_quarter · Health Issues
Issues relating to bioequivalence and related administrative procedures. Issues relating to prescription drug abuse. Issues relating to incentives for tamper-resistant formulations. H.R. 486: Stop Tampering of Prescription Pills Act of 2013.Issues relating to Medicare Part D rebates. Issues relating to health information technology. H.R. 1919: Safeguarding Americas Pharmaceuticals Act of 2013. Compounding and drug supply chain legislation. H.R. 3204: Drug Quality and Security Act. Issues relating to products containing high doses of acetaminophen. Issues relating to the labeling of generic drugs.
Client expense: Not reported · Firm income: $30,000
Government targets: HOUSE OF REPRESENTATIVES
2014 · third_quarter · Pharmacy
Issues related to bioequivalence and related administrative procedures; issues related to prescription drug abuse; issues related to the labeling of generic drugs; issues related to tamper resistant formulation of pharmaceutical drugs. The Life Sciences Jobs and Investment Act; Issues relating to Medicare Part D rebates; H.R. 486 - Stop Tampering of Prescription Pills Act of 2013; H.R. 1919 - Safeguarding Americas Pharmaceuticals Act of 2013
Client expense: Not reported · Firm income: $30,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2014 · third_quarter · Pharmacy
Controlled Drug Substances Act (21 USC 13) Stop Tampering of Prescription Pills Act of 2013 (H.R. 486)
Client expense: Not reported · Firm income: $50,000
Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2014 · third_quarter · Health Issues
general health issues, including, but not limited to, coverage and reimbursement; drug importation; research and development; biosimiliars; Stop Tampering of Prescription Pills Act of 2013 (H.R. 486) Safeguarding America's Pharmaceuticals Act of 2013
Client expense: Not reported · Firm income: $40,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2014 · third_quarter · Health Issues
State based medical licensure and regulation, health license portability, telemedicine and telehealth, prescription drug abuse, prescriber and patient education, responsible opioid prescribing, improvements to provider screening to prevent Medicare and Medicaid fraud, graduate medical education, multistate practice of medicine, interstate compact for medical licensure, HR2011, S1089, HR486, HR3077
Client expense: $165,000 · Firm income: Not reported
Government targets: Agency for Healthcare Research & Quality (AHRQ), Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Drug Enforcement Administration (DEA), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Office of Natl Drug Control Policy (NDCP), SENATE, Substance Abuse & Mental Health Services Administration (SAMHSA), Veterans Affairs, Dept of (VA), White House Office
2014 · third_quarter · Health Issues
Pharmaceutical Distribution Supply Chain Security (H.R. 1919 / S. 957 / S. 959); Electronic distribution of prescribing information; School Access to Emergency Epinephrine (H.R. 2094); Biosimilars; H.R. 8; H.R. 486 - the Stop Tampering of Prescription Pills (STOPP) Act; S.504 - Fair and Immediate Release of Generic Drugs Act; S.621 - The Safe Prescribing Act of 2013 /H.R.1285 H.R.460 - Patients Access to Treatments Act of 2013; House Energy & Commerce Committee's 21st Century Cures initiative
Client expense: Not reported · Firm income: $60,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2014 · third_quarter · Health Issues
Issues relating to bioequivalence and related administrative procedures; issues relating to prescription drug abuse; issues relating to incentives for tamper-resistant formulations; H.R. 486 (Stop Tampering of Prescription Pills Act of 2013); issues relating to Medicare Part D rebates; issues relating to health information technology; H.R. 1919 (Safeguarding America's Pharmaceuticals Act of 2013); compounding and drug supply chain legislation; H.R. 3204 (Drug Quality and Security Act); issues relating to products containing high doses of acetaminophen; issues relating to the labeling of generic drugs.
Client expense: $270,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2014 · second_quarter · Pharmacy
Implementation of FDASIA and GDUFA, Counterfeit Drugs/Import Safety, Drug Shortages, Labeling of Generic Drugs, Risk Evaluation Mitigation Strategies, Biosimilar Naming, Electronic Labeling for Pharmaceuticals, H.R. 2725, FDA Safety over Sequestration Act, S. 1413, FDA User Fee Protection Act, H.R. 2985, Combination Drug Development Incentive Act, H.R. 3742, Antibiotic Development to Advance Patient Treatment Act of 2013, H.R. 486, Stop Tampering of Prescription Pills Act of 2013H.R. 4437, Generic Drug Pricing Fairness Act
Client expense: $655,940 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE, White House Office
2014 · second_quarter · Pharmacy
Prescription Drug Abuse, STOPP Act H.R.486; S.Con.Res.8 (FY 2014 Budget) (provisions relating to healthcare and pharmeceuticals); Drug labeling, electronic labeling proposals; access to contraceptives; counterfeit drugs: "track-and-trace," H.R. 1919, Safeguarding America's Pharmaceuticals Act, and S.959, Pharmaceutical Quality, Security and Accountability Act; H.R. 3717 Helping Families in Mental Health Crisis Act of 2013.
Client expense: $870,000 · Firm income: Not reported
Government targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Patent & Trademark Office (PTO), SENATE, U.S. Trade Representative (USTR), White House Office
2014 · second_quarter · Health Issues
Issues relating to bioequivalence and related administrative procedures. Issues relating to prescription drug abuse. Issues relating to incentives for tamper-resistant formulations. H.R. 486: Stop Tampering of Prescription Pills Act of 2013.Issues relating to Medicare Part D rebates. Issues relating to health information technology. H.R. 1919: Safeguarding Americas Pharmaceuticals Act of 2013. Compounding and drug supply chain legislation. H.R. 3204: Drug Quality and Security Act. Issues relating to products containing high doses of acetaminophen. Issues relating to the labeling of generic drugs.
Client expense: Not reported · Firm income: $30,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2014 · second_quarter · Health Issues
Pharmaceutical Distribution Supply Chain Security (H.R. 1919 / S. 957 / S. 959); Electronic distribution of prescribing information; School Access to Emergency Epinephrine (H.R. 2094); Biosimilars; H.R. 8; H.R. 486 - the Stop Tampering of Prescription Pills (STOPP) Act; S.504 - Fair and Immediate Release of Generic Drugs Act; S.621 - The Safe Prescribing Act of 2013 /H.R.1285 H.R.460 - Patients Access to Treatments Act of 2013; House Energy & Commerce Committee's 21st Century Cures initiative
Client expense: Not reported · Firm income: $60,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2014 · second_quarter · Health Issues
The Prescription Drug Marketing Act;conterfit/pedigree issues Drug importation issues; Drug safety and inspection of drug manufacturing facilities; Prescription Drug Abuse;H.R. 1285 - To amend the Controlled Substances Act; H.R. 486 Stop Tampering of Prescription Pills Act of 2013;H.R. 672 - Prescription Drug Abuse Prevention and Treatment Act of 2013S. 216 - Safe Prescribing Act of 2013;S. 504 - Fair And Immediate Release of Generic Drugs Act;S. 348
Client expense: $680,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2014 · second_quarter · Budget/Appropriations
Highway Bill Re-authorization - Lobbied to promote federal aid to highway safety programs. No bill number. Entire bill. S. 2322 - Surface Transportation Re-authorization - Lobbied to promote the reauthorization of the Moving Ahead for Progress in the 21st Century (MAP-21) program, which funds highway and transit investments. Entire bill. Infrastructure Financing - promoting the growth of infrastructure financing through reforms of other federal economic programs. No bill. Highway Trust Fund Financing - promoting the growth of the highway trust fund through reforms of federal economic programs. No bill. HR 4435 - National Defense Authorization Act FY 2015 - A bill to authorize appropriations for fiscal year 2015 for military activities of the Department of Defense, for military construction, and for defense activities of the Department of Energy, to prescribe military personnel strengths for such fiscal year. Entire bill. HR 486 - Military Construction FY 2015 Appropriations - A bill making appropriations for military construction, the Department of Veterans Affairs, and related agencies for the fiscal year ending September 30, 2015. Lobbied for Davis-Bacon regulations. HR 4745 - FY 2015 Transportation - HUD Appropriations - A bill making appropriations for the Departments of Transportation, and Housing and Urban Development, and related agencies for the fiscal year ending September 30, 2015. Entire bill.
Client expense: $220,000 · Firm income: Not reported
Government targets: Energy, Dept of, HOUSE OF REPRESENTATIVES, Labor, Dept of (DOL), SENATE, Transportation, Dept of (DOT), White House Office
2014 · second_quarter · Health Issues
State based medical licensure and regualtion, licensure portability, interstate compacts, telemedicine, telehealth, prescription drug abuse, prescriber and patient education, responsible opioid prescribing, provider screening improvements to prevent Medicare and Medicaid fraud, graduate medical education, multistate practice of medicine, HR 2011, S1089, HR486, HR3077
Client expense: $155,000 · Firm income: Not reported
Government targets: Agency for Healthcare Research & Quality (AHRQ), Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Drug Enforcement Administration (DEA), Executive Office of the President (EOP), Federal Trade Commission (FTC), Food & Drug Administration (FDA), Government Accountability Office (GAO), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Office of Natl Drug Control Policy (NDCP), SENATE, Substance Abuse & Mental Health Services Administration (SAMHSA), Veterans Affairs, Dept of (VA), White House Office
2014 · second_quarter · Pharmacy
Issues related to bioequivalence and related administrative procedures; issues related to prescription drug abuse; issues related to the labeling of generic drugs; issues related to tamper resistant formulation of pharmaceutical drugs. The Life Sciences Jobs and Investment Act; Issues relating to Medicare Part D rebates; H.R. 486 Stop Tampering of Prescription Pills Act of 2013; H.R. 1919 Safeguarding Americas Pharmaceuticals Act of 2013
Client expense: Not reported · Firm income: $30,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2014 · second_quarter · Health Issues
Issues relating to bioequivalence and related administrative procedures; issues relating to prescription drug abuse; issues relating to incentives for tamper-resistant forumulations; H.R. 486 (Stop Tampering of Prescription Pills Act of 2013); issues relating to Medicare Part D rebates; issues relating to health information technology; H.R. 1919 (Safeguarding America's Pharmaceuticals Act of 2013); compounding and drug supply chain legislation; H.R. 3204 (Drug Quality and Security Act); issues relating to productscontaining high doses of acetaminophen; issues relating to the labeling of generic drugs.
Client expense: $210,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2014 · second_quarter · Health Issues
General health issues, including, but not limited to, coverage and reimbursement; drug imporation; research and development; biosimiliars; Stop Tampering of Prescription Pills Act of 2013 (H.R. 486); Safeguarding America's Pharmaceuticals Act of 2013
Client expense: Not reported · Firm income: $30,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2014 · first_quarter · Pharmacy
Implementation of Biosimilars in the Affordable Care Act (ACA), Implementation of FDASIA and GDUFA, Counterfeit Drugs/Import Safety, Prescription Drug Importation/Re-Importation, Drug Shortages, Labeling of Generic Drugs, Risk Evaluation Mitigation Strategies, Biosimilar Naming, Electronic Labeling for Pharmaceuticals, H.R. 486 - Stop Tampering of Prescription Pills Act of 2013, H.R. 2725 - FDA Safety over Sequestration Act, H.R. 3204 - Drug Quality and Security Act,S. 957 - Drug Supply Chain Security Act S. 1413 FDA User Fee Protection Act
Client expense: $660,000 · Firm income: Not reported
Government targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Office of Management & Budget (OMB), SENATE, Vice President of the U.S., White House Office
2014 · second_quarter · Pharmacy
Controlled Drug Substances Act (21 USC 13) Stop Tampering of Prescription Pills Act of 2013 (H.R. 486)
Client expense: Not reported · Firm income: $50,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2014 · first_quarter · Health Issues
Issues relating to bioequivalence and related administrative procedures. Issues relating to prescription drug abuse. Issues relating to incentives for tamper-resistant formulations. H.R. 486: Stop Tampering of Prescription Pills Act of 2013.Issues relating to Medicare Part D rebates. Issues relating to health information technology. H.R. 1919: Safeguarding Americas Pharmaceuticals Act of 2013. Compounding and drug supply chain legislation. H.R. 3204: Drug Quality and Security Act. Issues relating to products containing high doses of acetaminophen. Issues relating to the labeling of generic drugs.
Client expense: Not reported · Firm income: $30,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2014 · first_quarter · Pharmacy
Implementation of Biosimilars in the Affordable Care Act (ACA), Implementation of FDASIA and GDUFA, Counterfeit Drugs/Import Safety, Prescription Drug Importation/Re-Importation, Drug Shortages, Labeling of Generic Drugs, Risk Evaluation Mitigation Strategies, Biosimilar Naming, Electronic Labeling for Pharmaceuticals, H.R. 486 - Stop Tampering of Prescription Pills Act of 2013, H.R. 2725 - FDA Safety over Sequestration Act, H.R. 3204 - Drug Quality and Security Act,H.R. 3709 - Protecting Consumers Access to Generic Drugs Act of 2013 S. 214 - Preserve Access to Affordable Generics Act S. 957 - Drug Supply Chain Security Act S. 1413 FDA User Fee Protection Act
Client expense: $660,626 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Federal Trade Commission (FTC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of the Vice President of the United States, SENATE, U.S. Trade Representative (USTR), White House Office
2014 · first_quarter · Health Issues
Pharmaceutical Distribution Supply Chain Security; Electronic distribution of prescribing information; H.R. 3204, the Drug Quality and Security Act; Compounding; Generic Labeling; Biosimilars; H.R. 486, the Stop Tampering of Prescription Pills (STOPP) Act; S. 214, the Preserve Access to Affordable Generics; S. 504, the Fair and Immediate Release of Generic Drugs Act; H.R. 2725, the FDA Safety Over Sequestration Act of 2013; S. 621, the Safe Prescribing Act of 2013Risk Evaluation Mitigation Strategies; H.R. 460, Patients' Access to Treatments Act of 2013; implementation of the Generic Drug User Fee Act
Client expense: $520,000 · Firm income: Not reported
Government targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Office of Management & Budget (OMB), SENATE
2014 · first_quarter · Pharmacy
Prescription Drug Abuse, STOPP Act H.R.486; S.Con.Res.8 (FY 2014 Budget) (provisions relating to healthcare and pharmeceuticals); Drug labeling, electronic labeling proposals; access to contraceptives; counterfeit drugs: "track-and-trace," H.R. 1919, Safeguarding America's Pharmaceuticals Act, and S.959, Pharmaceutical Quality, Security and Accountability Act; H.R. 3717 Helping Families in Mental Health Crisis Act of 2013.
Client expense: $1,160,000 · Firm income: Not reported
Government targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Patent & Trademark Office (PTO), SENATE, U.S. Trade Representative (USTR), White House Office
2014 · first_quarter · Health Issues
Pharmaceutical Distribution Supply Chain Security (H.R. 1919 / S. 957 / S. 959); Electronic distribution of prescribing information; School Access to Emergency Epinephrine (H.R. 2094); Biosimilars; H.R. 8; H.R. 486 - the Stop Tampering of Prescription Pills (STOPP) Act; S.504 - Fair and Immediate Release of Generic Drugs Act; S.621 - The Safe Prescribing Act of 2013 /H.R.1285 H.R.460 - Patients Access to Treatments Act of 2013
Client expense: Not reported · Firm income: $60,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2014 · first_quarter · Health Issues
Pharmaceutical Distribution Supply Chain Security (H.R. 1919 / S. 957 / S. 959); Electronic distribution of prescribing information; School Access to Emergency Epinephrine (H.R. 2094); Biosimilars; H.R. 8; H.R. 486 - the Stop Tampering of Prescription Pills (STOPP) Act; S.504 - Fair and Immediate Release of Generic Drugs Act; S.621 - The Safe Prescribing Act of 2013 /H.R.1285 H.R.460 - Patients Access to Treatments Act of 2013
Client expense: Not reported · Firm income: $60,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2014 · first_quarter · Health Issues
State based medical licensure and regulation, license portability, telemedicine/telehealth, prescription drug abuse, prescriber and patient education, responsible opioid prescribing, improved provider screening to combat Medicare and Medicaid fraud, graduate medical education, mulitstate practice of medicine, interstate compact for medical licensure, HR 2011, S1089, HR486, HR3077
Client expense: $150,000 · Firm income: Not reported
Government targets: Agency for Healthcare Research & Quality (AHRQ), Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Drug Enforcement Administration (DEA), Executive Office of the President (EOP), Federal Trade Commission (FTC), Food & Drug Administration (FDA), Government Accountability Office (GAO), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Office of Natl Drug Control Policy (NDCP), SENATE, Substance Abuse & Mental Health Services Administration (SAMHSA), Veterans Affairs, Dept of (VA), White House Office
2014 · first_quarter · Health Issues
The Prescription Drug Marketing Act;conterfit/pedigree issues Drug importation issues; Drug safety and inspection of drug manufacturing facilities; Prescription Drug Abuse;H.R. 1285 - To amend the Controlled Substances Act; H.R. 486 Stop Tampering of Prescription Pills Act of 2013;H.R. 672 - Prescription Drug Abuse Prevention and Treatment Act of 2013S. 216 - Safe Prescribing Act of 2013;S. 504 - Fair And Immediate Release of Generic Drugs Act;S. 348
Client expense: $420,000 · Firm income: Not reported
Government targets: Federal Communications Commission (FCC), HOUSE OF REPRESENTATIVES, SENATE
2014 · first_quarter · Health Issues
General health care issues, including, but not limited to, coverage and reimbursement; drug importation; research and development; biosimiliars; Stop Tampering of Prescription Pills Act of 2013 (H.R. 486)
Client expense: Not reported · Firm income: $30,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2014 · first_quarter · Health Issues
Issues relating to bioequivalence and related administrative procedures; issues relating to prescription drug abuse; issues relating to incentives for tamper-resistant forumulations; H.R. 486 (Stop Tampering of Prescription Pills Act of 2013); issues relating to Medicare Part D rebates; issues relating to health information technology; H.R. 1919 (Safeguarding America's Pharmaceuticals Act of 2013); compounding and drug supply chain legislation; H.R. 3204 (Drug Quality and Security Act); issues relating to productscontaining high doses of acetaminophen; issues relating to the labeling of generic drugs.
Client expense: $440,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2014 · first_quarter · Pharmacy
Controlled Drug Substances Act (21 USC 13) Stop Tampering of Prescription Pills Act of 2013 (H.R. 486)
Client expense: Not reported · Firm income: $40,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2013 · fourth_quarter · Health Issues
Pharmaceutical Distribution Supply Chain Security (H.R. 1919 / S. 957 / S. 959); Electronic distribution of prescribing information; School Access to Emergency Epinephrine (H.R. 2094); Biosimilars; H.R. 8; H.R. 486 - the Stop Tampering of Prescription Pills (STOPP) Act; S.504 - Fair and Immediate Release of Generic Drugs Act; S.621 - The Safe Prescribing Act of 2013 /H.R.1285 H.R.460 - Patients Access to Treatments Act of 2013
Client expense: Not reported · Firm income: $50,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2013 · fourth_quarter · Health Issues
The Prescription Drug Marketing Act;conterfit/pedigree issues Drug importation issues; Drug safety and inspection of drug manufacturing facilities; Prescription Drug Abuse;H.R. 1285 - To amend the Controlled Substances Act; H.R. 486 Stop Tampering of Prescription Pills Act of 2013;H.R. 672 - Prescription Drug Abuse Prevention and Treatment Act of 2013S. 216 - Safe Prescribing Act of 2013;S. 504 - Fair And Immediate Release of Generic Drugs Act;S. 348
Client expense: $730,000 · Firm income: Not reported
Government targets: Federal Communications Commission (FCC), HOUSE OF REPRESENTATIVES, SENATE
2013 · fourth_quarter · Health Issues
Issues relating to bioequivalence and related administrative procedures. Issues relating to prescription drug abuse. Issues relating to incentives for tamper-resistant formulations. H.R. 486: Stop Tampering of Prescription Pills Act of 2013.Issues relating to Medicare Part D rebates. Issues relating to health information technology. H.R. 1919: Safeguarding Americas Pharmaceuticals Act of 2013. Compounding and drug supply chain legislation. H.R. 3204: Drug Quality and Security Act. Issues relating to products containing high doses of acetaminophen.
Client expense: Not reported · Firm income: $30,000
Government targets: HOUSE OF REPRESENTATIVES
2013 · fourth_quarter · Health Issues
Pharmaceutical Distribution Supply Chain Security (H.R. 1919 / S. 957 / S. 959); Electronic distribution of prescribing information; School Access to Emergency Epinephrine (H.R. 2094); Biosimilars; H.R. 8; H.R. 486 - the Stop Tampering of Prescription Pills (STOPP) Act; S.504 - Fair and Immediate Release of Generic Drugs Act; S.621 - The Safe Prescribing Act of 2013 /H.R.1285 H.R.460 - Patients Access to Treatments Act of 2013
Client expense: Not reported · Firm income: $50,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2013 · fourth_quarter · Health Issues
Pharmaceutical Distribution Supply Chain Security; Electronic distribution of prescribing information; H.R. 3204, the Drug Quality and Security Act; Compounding; H.R. 2094 and S. 1503, the School Access to Emergency Epinephrine Act; Biosimilars; H.R. 486, the Stop Tampering of Prescription Pills (STOPP) Act; S. 214, the Preserve Access to Affordable GenericsS. 504, Fair and Immediate Release of Generic Drugs Act; H.R. 1285, S. 621, the Safe Prescribing Act of 2013; H.R. 460, Patients' Access to Treatments Act of 2013; H.R. 2725, the FDA Safety Over Sequestration Act 2013; S. 1545, the PEPFAR Stewardship and Oversight Act; Generic Labeling
Client expense: $360,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2013 · fourth_quarter · Pharmacy
Prescription Drug Abuse, STOPP Act H.R.486; S.Con.Res.8 (FY 2014 Budget) (provisions relating to healthcare and pharmeceuticals); Drug labeling, electronic labeling proposals; access to contraceptives; counterfeit drugs: "track-and-trace," H.R. 1919, Safeguarding America's Pharmaceuticals Act, and S.959, Pharmaceutical Quality, Security and Accountability Act.
Client expense: $800,000 · Firm income: Not reported
Government targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Patent & Trademark Office (PTO), SENATE, U.S. Trade Representative (USTR), White House Office
2013 · fourth_quarter · Health Issues
General health care issues, including, but not limited to, coverage and reimbursement; drug importation; research and development; biosimiliars; Stop Tampering of Prescription Pills Act of 2013 (H.R. 486)
Client expense: Not reported · Firm income: $40,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE